Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations

About this update from Perrigo Company Plc

[{"type":"text","content":"Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day","length":130,"tagName":"p","attribs":{}},{"type":"text","content":"Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands","length":117,"tagName":"p","attribs":{}},{"type":"text","content":"Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range","length":171,"tagName":"p","attribs":{}},{"type":"text","content":"DUBLIN, May 7, 2025 /PRNewswire/ --","length":35,"tagName":"p"},{"type":"image","alt":"Perrigo Company (PRNewsfoto/Perrigo Company plc)","displaySize":"","headline":null,"caption":"Perrigo Company (PRNewsfoto/Perrigo Company plc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":163,"url":"https://media.zenfs.com/en/prnewswire.com/58a55f8503cfc72bd230dcf598941232"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cimhyXXkk36wYSGzHrrleA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/58a55f8503cfc72bd230dcf598941232","width":400,"height":163}},"href":"https://mma.prnewswire.com/media/2394816/Perrigo_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"First Quarter 2025 Highlights:","length":30,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested businesses, exited product lines and currency translation. ","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Organic1 net sales decreased 0.4% as higher net sales in the Nutrition, Upper Respiratory and Healthy Lifestyle categories were more than offset by previously disclosed net lost distribution of lower margin products in U.S. Store Brand of 0.8%, the lack of a prior year benefit in the Women's Health category of 1.4% from initial retailer stocking of Opill® which launched at the end of the quarter, and lower net sales in the Digestive Health category. ","length":457,"tagName":"p"}]},{"val":[{"type":"text","content":"Excluding previously disclosed net lost distribution of lower margin products in U.S. Store Brand of 0.8%, ...

More updates from Perrigo Company Plc